Article Text

Download PDFPDF

Correspondence response
Response to: ‘Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases’. Screening for comorbidities: what is the remit of rheumatologists?
  1. Athan Baillet1,
  2. Laure Gossec2,
  3. Maxime Dougados3
  1. 1Department of Rheumatology, GREPI-UGA EA7408, Grenoble, France
  2. 2Department of Rheumatology, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Paris, France
  3. 3Department of Rheumatology, Paris Descartes University,—Hôpital Cochin. Assistance Publique—Hôpitaux de Paris. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
  1. Correspondence to Dr Athan Baillet, Service de Rhumatologie CHU Grenoble, Av de Kimberley, Echirolles 38434, France; abaillet{at}

Statistics from

We thank Castañeda et al1 for their interest in our paper2 and are pleased to have the opportunity to respond to their comments in order to clarify what part of the management of comorbidities we believe to be within the remit of rheumatologists, that is, what is likely to be done by the rheumatologist and what rheumatologists are able to do in the daily practice.

The European League Against Rheumatism (EULAR) task force anticipated that the screening of a wide scope of comorbidities would make the final process too complex or too extensive to be implemented. The EULAR task force acknowledged that fibromyalgia impacts on the assessment of the disease activity and response to treatment of chronic …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles